Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that new
preclinical data supporting the clinical development of its
proprietary next generation antibody-drug conjugate (ADC) and
innovative tetra-specific ANKET® will be presented at the SITC
Annual Meeting 2024.
“We are thrilled to share our latest preclinical data at the
SITC Annual Meeting, highlighting the potential of IPH6501, our
tetra-specific NK cell engager and IPH4502, our innovative ADC
targeting Nectin-4. These findings underscore our commitment to
advancing next-generation immunotherapies and reflect significant
progress in the development of our drug candidates. We look forward
to engaging with the scientific community as we continue to push
the boundaries of next generation immunotherapies,” commented
Pr. Eric Vivier, Chief Scientific Officer of Innate
Pharma.
Details of the presentations
Society for Immunotherapy of Cancer (SITC) 39th Annual
Meeting | 6-10 November, Houston, Texas and Virtual
- Harnessing NK Cells in Cancer Therapies Session 107d: NK Cells
and Innate Immunity Presentation Type: Oral Presentation Session
Date and Time: Friday, Nov. 8, 2024, 3:50-5:25pm CST Presentation
Time: 4:35pm CST Speaker: Eric Vivier, Chief Scientific Officer,
Innate Pharma (co-chair of the session)
- Preclinical Characterization of IPH6501: A Novel IL2v-Armed
Tetraspecific NK Cell Engager Targeting CD20 in Relapsed or
Refractory B cell Non-Hodgkin Lymphoma Subtypes and Post-CAR-T
Therapy. Abstract Number: 1083 Presentation Type: Poster
Presentation Primary Category: Immuno-Conjugates and Chimeric
Molecules Poster Presentation Day: Friday, Nov. 8, 2024
- IPH45, a next-generation antibody-drug conjugate (ADC)
targeting Nectin-4 Abstract Number: 1056 Presentation Type: Poster
Presentation Primary Category: Immuno-Conjugates and Chimeric
Molecules Poster Presentation Day: Saturday, Nov. 9, 2024
More information can be found on the JITC website.
Protein & Antibody Engineering Summit (PEGS) Europe |
November 5-7, Barcelona, Spain and virtual
In addition, the presentation entitled « A Next-Generation ADC
for Nectin-4 Expressing Tumours: Preclinical Characterisation of
IPH45, a Novel and Differentiated Exatecan-Based ADC Targeting
Nectin-4 » was presented at the PEGS Europe Summit. The
presentation is available on the Company website, in the
publications section.
About IPH4502
IPH4502 is a novel topoisomerase I inhibitor Antibody Drug
Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
Nectin-4 is a cell membrane adhesion protein overexpressed in
several solid tumors, including urothelial, breast, lung, ovarian,
and pancreatic cancers, with limited expression in normal
tissues.
In non-clinical models, IPH4502 is well tolerated and shows
anti-tumor efficacy in vitro and in vivo.
In September 2024, the U.S Food and Drug Administration cleared
Innate’s investigational new drug (IND) application to initiate a
Phase 1 clinical study of IPH4502 in Nectin-4 expressing solid
tumor indications.
About IPH6501
IPH6501 is the first Antibody-based NK cell Engager Therapeutic
to co-engage activating receptors on NK cells (NKp46 and CD16),
IL-2R (but not a subunit) through a variant of human IL-2, and a
tumor antigen (CD20) via a single molecule, hence providing
proliferation and activation signals targeted to NK cells and
promoting their cytotoxic activity against CD20 expressing
malignant cells.
IPH6501 has shown better anti-tumor efficacy than approved
benchmark antibodies in preclinical tumor models (Demaria, EHA
2023).
IPH6501 is currently being evaluated in a Phase 1/2 multicenter
trial (NCT06088654), investigating the safety and tolerability of
IPH6501 in patients with Relapsed and/or Refractory CD20-expressing
B-cell Non-Hodgkin’s Lymphoma.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through three therapeutic approaches: monoclonal antibodies,
multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK
cell Engager Therapeutics) proprietary platform and Antibody Drug
Conjugates (ADC).
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, several ANKET® drug candidates to
address multiple tumor types as well as IPH4502 a differentiated
ADC in development in solid tumors.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995. The
use of certain words, including “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “may,” “might,” “potential,”
“expect” “should,” “will,” or the negative of these and similar
expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s reliance on third parties to manufacture its product
candidates, the Company’s commercialization efforts and the
Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2023, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public by
the Company. References to the Company’s website and the AMF
website are included for information only and the content contained
therein, or that can be accessed through them, are not incorporated
by reference into, and do not constitute a part of, this press
release.
In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any
specified time frame or at all. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107232735/en/
For additional information, please contact:
Investors Innate Pharma
Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr Media
Relations NewCap Arthur Rouillé Tel.: +33 (0)1 44
71 00 15 innate@newcap.eu
Innate Pharma (EU:IPH)
過去 株価チャート
から 10 2024 まで 11 2024
Innate Pharma (EU:IPH)
過去 株価チャート
から 11 2023 まで 11 2024
